Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5866406 | 0.94 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL6971038 | 0.82 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL3630271 | 0.78 | GRIN2B (0.62) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL14377378 | 0.76 | HTT (0.47) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL13303078 | 0.73 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL20494874 | 0.72 | HTT (0.50) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL16095894 | 0.72 | HTT (0.50) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL15617322 | 0.72 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL14800843 | 0.72 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL28855466 | 0.72 | MEN1 (0.50) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053213-B2 | Therapeutic heterocycles | ASTRAZENECA AB (SE) | 2006-05-30 | — | — | US | disclosed |
| EP-1307202-B1 | METHOD FOR THE TREATMENT OF OVERACTIVE BLADDER | ASTRAZENECA AB (SE) | 2006-05-17 | — | — | EP | disclosed |
| US-20040248914-A1 | Method for the treatment of overactive bladder | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | US | disclosed |
| EP-1450805-A1 | METHOD FOR THE TREATMENT OF OVERACTIVE BLADDER | AstraZeneca AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| US-20030187255-A1 | Therapeutic heterocycles | MILLER SCOTT CARSON (US) | 2003-10-02 | — | — | US | disclosed |
| US-20030139433-A1 | Method for the treatment of overactive bladder | ASTRAZENECA AB (SE) | 2003-07-24 | — | — | US | disclosed |
| WO-2003037341-A1 | METHOD FOR THE TREATMENT OF OVERACTIVE BLADDER | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
| EP-1307202-A1 | METHOD FOR THE TREATMENT OF OVERACTIVE BLADDER | AstraZeneca AB (SE) | 2003-05-07 | — | — | EP | disclosed |
| US-6444809-B1 | ANTIHISTAMINES | ZENECA LIMITED (GB) | 2002-09-03 | — | — | US | disclosed |
| WO-2001097811-A1 | METHOD FOR THE TREATMENT OF OVERACTIVE BLADDER | ASTRAZENECA AB (SE) | 2001-12-27 | — | — | WO | disclosed |
| US-6124279-A | NEUROKININ A ANTAGONISTS, ANTIASTHMATIC AGENTS | ZENECA LIMITED (GB) | 2000-09-26 | — | — | US | disclosed |
| US-5990130-A | NOVEL 4-SUBSTITUTED PIPERIDINE DERIVATIVES WHICH ANTAGONIZE NEUROKININ; USEFUL IN TREATMENT OF ASMTHMA AND RELATED CONDITIONS | ZENECA LIMITED (GB) | 1999-11-23 | — | — | US | disclosed |
| EP-0714392-B1 | HETEROCYCLES USEFUL AS NEUROKININ ANTAGONISTS | ZENECA LTD (GB) | 1998-11-04 | — | — | EP | disclosed |
| US-5567700-A | USEFUL FOR TREATING ASTHMA | ZENECA LIMITED (GB) | 1996-10-22 | — | — | US | disclosed |
| EP-0714392-A1 | HETEROCYCLES USEFUL AS NEUROKININ ANTAGONISTS | ZENECA LIMITED (GB) | 1996-06-05 | — | — | EP | disclosed |
| WO-1995005377-A1 | HETEROCYCLES USEFUL AS NEUROKININ ANTAGONISTS | ZENECA LIMITED (GB) | 1995-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248914-A1 | Method for the treatment of overactive bladder | TACR1, TACR2, OGFR | SMN1; SMN2 3444/4885NPC1 3577/4885RAB9A 2716/4885 |
| US-20030139433-A1 | Method for the treatment of overactive bladder | QDPR, PDE3A, HNMT | SMN1; SMN2 1028/4885NPC1 4570/4885RAB9A 3779/4885 |
| US-20030187255-A1 | Therapeutic heterocycles | BDKRB2, TK2, TACR2 | SMN1; SMN2 1152/4885NPC1 387/4885RAB9A 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.